VIVUS (NASDAQ:VVUS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Saturday.

According to Zacks, “VIVUS' lead product, Qsymia's sales have been weak since its launch due to high out-of-pocket cost burden for patients due to lack of reimbursement for the product. Low coverage or exclusion of anti-obesity medications in insurance plans is a concern. However, VIVUS is working on boosting Qsymia sales by expanding reimbursement and promotional initiatives. However, challenges in the obesity market remain. Nonetheless, we are positive on VIVUS’ partnership agreements for Stendra as these provide the company with a steady stream of cash flow from upfront and milestone payments. The recent acquisition of tacrolimus for the PAH indication also looks good as the drug address a fundamental cause instead of treating symptoms. Shares of the company have underperformed the industry in the past one year. Estimates have remained stable ahead of the Q4 earnings results. The company has a positive record of earnings surprises in recent quarters.”

Separately, ValuEngine raised VIVUS from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd.

Shares of VIVUS (NASDAQ:VVUS) traded down $0.01 on Friday, hitting $0.53. The company had a trading volume of 191,900 shares, compared to its average volume of 775,404. The company has a quick ratio of 7.09, a current ratio of 7.47 and a debt-to-equity ratio of 643.86. The stock has a market cap of $54.16, a price-to-earnings ratio of 1.59 and a beta of 0.80. VIVUS has a twelve month low of $0.48 and a twelve month high of $1.38.

VIVUS (NASDAQ:VVUS) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.07. The business had revenue of $15.19 million for the quarter, compared to analyst estimates of $16.00 million. VIVUS had a return on equity of 344.23% and a net margin of 26.71%. The business’s quarterly revenue was up 13.8% on a year-over-year basis. During the same period last year, the company posted ($0.09) EPS. equities research analysts forecast that VIVUS will post -0.32 EPS for the current year.

Institutional investors and hedge funds have recently modified their holdings of the stock. D. E. Shaw & Co. Inc. raised its position in VIVUS by 1,233.1% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,205,800 shares of the biopharmaceutical company’s stock valued at $1,230,000 after purchasing an additional 1,115,352 shares during the period. Stifel Financial Corp raised its position in VIVUS by 584.0% in the fourth quarter. Stifel Financial Corp now owns 435,829 shares of the biopharmaceutical company’s stock valued at $24,132,000 after purchasing an additional 372,114 shares during the period. TIAA CREF Investment Management LLC raised its position in VIVUS by 59.8% in the first quarter. TIAA CREF Investment Management LLC now owns 558,531 shares of the biopharmaceutical company’s stock valued at $782,000 after purchasing an additional 208,930 shares during the period. State Street Corp raised its position in VIVUS by 11.3% in the first quarter. State Street Corp now owns 1,761,029 shares of the biopharmaceutical company’s stock valued at $2,464,000 after purchasing an additional 178,565 shares during the period. Finally, Geode Capital Management LLC raised its position in VIVUS by 1.0% in the first quarter. Geode Capital Management LLC now owns 685,494 shares of the biopharmaceutical company’s stock valued at $959,000 after purchasing an additional 7,119 shares during the period. 31.30% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/06/vivus-vvus-rating-lowered-to-hold-at-zacks-investment-research.html.

VIVUS Company Profile

VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

Get a free copy of the Zacks research report on VIVUS (VVUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.